Topical rapamycin (sirolimus) for facial angiofibromas
Open Access
- 1 January 2013
- journal article
- drug profile
- Published by Medknow in Indian Dermatology Online Journal
- Vol. 4 (1), 54-57
- https://doi.org/10.4103/2229-5178.105488
Abstract
Rapamycin (sirolimus) is a fungal fermentation product that inhibits the proper functioning of a serine/threonine protein kinase in mammalian cells eponymously named mammalian target of rapamycin, or mTOR. Rapamycin is a novel class of anticancer and immunosuppressant drugs targeting the proteins at molecular level. Rapamycin (sirolimus) is routinely incorporated in drug-eluting stents used for cardiac angioplasty. In recent years, rapamycin was found to be efficacious in managing the symptom complex of tuberous sclerosis, i.e. renal angiomyolipoma, giant cell astrocytoma and pulmonary lymphangiomyomatosis. Various investigators have also proved that topically applied rapamycin causes regression of facial angiofibromas, giving better cosmetic results.Keywords
This publication has 31 references indexed in Scilit:
- The mTOR Signalling Pathway in Human CancerInternational Journal of Molecular Sciences, 2012
- mTOR inhibitors: A novel class of anti-cancer agentsInfectious Agents and Cancer, 2012
- Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: A pilot study of four patientsAustralasian Journal of Dermatology, 2011
- An emerging role for TOR signaling in mammalian tissue and stem cell physiologyDevelopment, 2011
- mTOR Inhibitors in Advanced Renal Cell CarcinomaHematology/Oncology Clinics of North America, 2011
- Efficacy and Safety of Sirolimus in LymphangioleiomyomatosisNew England Journal of Medicine, 2011
- Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosisKorean Journal of Pediatrics, 2011
- Regression of Subependymal Giant Cell Astrocytoma With Rapamycin in Tuberous Sclerosis ComplexJournal of Child Neurology, 2008
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or LymphangioleiomyomatosisNew England Journal of Medicine, 2008
- Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor TemsirolimusCancer Research, 2006